spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  lipodystrophy 

 HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jun 2020
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2020
Akcea Announces Appointment of New Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2020
Lilly plans donation of 200,000 insulin KwikPens over next three years to support lower-income communities
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 4 Mar 2019
Lilly to Introduce Lower-Priced Insulin
Biopharmaceuticals Endocrinology Product Launch
 HSMN NewsFeed - 19 Dec 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Oct 2018
Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2018
Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Jul 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Jun 2018
Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2018
Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 26 Mar 2018
FDA approves inclusion of data from safety outcomes trial in the Tresiba(R) label
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 15 Mar 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Feb 2018
Galmed Announces ARRIVE Study Data
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2017
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Nov 2017
Ionis Announces Management Transitions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2017
SPINRAZA(R) (nusinersen) Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 May 2017
Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 28 Mar 2017
Akcea Therapeutics Announces Three Additions to Board of Directors
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Feb 2016
Galmed Pharmaceuticals Announces Retirement of Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2016
Novo Nordisk Launches Tresiba(R) (insulin degludec injection 200 Units/mL) in the United States
Biopharmaceuticals Endocrinology Product Launch
 HSMN NewsFeed - 19 Jan 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 5 Jan 2016
Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 14 Jan 2013
Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Oct 2012
Fate Therapeutics Appoints Christian Weyer As President And Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 22 Jun 2012
Theratechnologies Provides Regulatory Update on Tesamorelin
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 May 2012
FDA Approves Levemir(R) for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 2 Apr 2012
FDA Approves Levemir(R) Pregnancy Category Change for Women with Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 3 Feb 2011
Theratechnologies and Ferrer Announce a Distribution & Licensing Agreement for Tesamorelin in Europe
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 1 Dec 2010
Theratechnologies Welcomes the Arrival of Its New President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Nov 2010
FDA Approves EGRIFTA(TM) (Tesamorelin for Injection): The First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-Infected Patients With Lipodystrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jan 2010
Theratechnologies Reports Date for FDA Advisory Committee Review of the Tesamorelin New Drug Application
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 29 Oct 2008
EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory
 HSMN NewsFeed - 1 Oct 2007
Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 9 Aug 2007
Theratechnologies Appoints Dr. Pierre Caudrelier as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2007
144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS
 HSMN NewsFeed - 25 Jun 2007
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir(R)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Apr 2007
Abbott Agrees With World Health Organization (WHO) Director-General to Expand Access to Kaletra/Aluvia (lopinavir/ritonavir)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 31 Jan 2007
Theratechnologies Launches Confirmatory Phase 3 Trial Testing TH9507 in HIV-Associated Lipodystrophy
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Interim Analysis of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 25 Oct 2006
Theratechnologies: Last Patient Treated in Pivotal TH9507 Trial
Biopharmaceuticals
 HSMN NewsFeed - 14 Jul 2006
Conjuchem announces clinical hold of its DAC(TM):GRF Program in HIV Lipodystrophy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 27 Jun 2006
Novo Nordisk Prevails in sanofi-aventis Challenge to Levemir(R) - Up to 24 Hours Duration of Action and Other Claims Upheld
Biopharmaceuticals Litigation
 HSMN NewsFeed - 11 May 2006
ConjuChem Announces New Executive Vice President, Research and Development
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 39

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 39 additional stories matching:
lipodystrophy
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.